Professor Narci Teoh

Senior Staff Specialist, Gastroenterology & Hepatology, Canberra Health Services
Honorary Professor, ANU School of Medicine and Psychology

Narci Teoh is a Professor at the Australian National University Medical School, Senior Staff Specialist in Gastroenterology and Hepatology at The Canberra Hospital, who is also engaged in part-time private practice at GastrotrACT Gastroenterological Services, Brindabella and Mugga Warra Endoscopy Centres in Garran, Canberra.

Her clinical interests in gastroenterology include coeliac disease, as well as digestive tract cancers especially in the prevention, screening and management of cancers that arise in the large bowel and liver. She also has expertise in the care and treatment of patients living with hepatitis B, fatty liver disease and is committed to patient education and advocacy in these areas.


  • Gastroenterology

Research interests

1. Liver carcinogenesis: role of DNA repair in hepatocellular carcinoma development

2. Liver ischaemia reperfusion injury (IRI): mechanisms and novel hepatoprotective strategies against IRI

3. Obesity-related liver disease: microvascular dysfunction and predisposition to liver cancer

  • Gardiner OAM PhD, F, Bishop, L, Gale, L et al. 2020, 'Poor access to kidney disease management services in susceptible patient populations in rural Australia is associated with increased aeromedical retrievals for acute renal care', Internal Medicine Journal, vol. 50, no. 8, pp. 951-959.
  • Wardell, R, Chitturi, S, Teoh, N et al. 2020, 'When the liver gets stiff, the tough get moving', Journal of Gastroenterology and Hepatology, pp. -.
  • Teoh, N 2019, 'Recent advances in the management of hepatocellular carcinoma: First, cut � is the deepest or is it "no-touch" and exercise?', Journal of Gastroenterology and Hepatology, vol. 34, no. 3, pp. 481-482.
  • Farrell, G, Schattenberg, J, Leclercq, I et al. 2019, 'Mouse Models of Nonalcoholic Steatohepatitis: Toward Optimization of Their Relevance to Human Nonalcoholic Steatohepatitis', Hepatology, vol. 69, no. 5, pp. 2241-2257.
  • Gardiner OAM PhD, F, Richardson, A, Bishop, L et al. 2019, 'Health care for older people in rural and remote Australia: challenges for service provision', Medical Journal of Australia, vol. 211, no. 8, pp. 363-364.
  • Farrell, G, Wardell, R, Teoh, N et al 2019, 'Non-alcoholic fatty liver disease', Internal Medicine Journal, vol. 49, no. 5, pp. 681-683.
  • Liang, J, Teoh, N, Xu, L et al. 2018, 'Dietary cholesterol promotes steatohepatitis related hepatocellular carcinoma through dysregulated metabolism and calcium signaling', Nature Communications, vol. 9, pp. 1-13.
  • Irudayaswamy, A, Muthiah, M, Zhou, L et al. 2018, 'Long-Term Fate of Human Fetal Liver Progenitor Cells Transplanted in Injured Mouse Livers', Stem Cells, vol. 36, no. 1, pp. 103-113.
  • Haczeyni, F, Yeh, M, Ioannou, G et al 2018, 'Mouse models of non-alcoholic steatohepatitis: A reflection on recent literature', Journal of Gastroenterology and Hepatology, vol. 33, no. 7, pp. 1312-1320.
  • Arfianti, A, Barn, V, Pok, S et al. 2017, 'Diabetes augments obesity in accelerating liver tumour development: role of oxidative stress-induced JNK signalling and DNA damage response', 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, Elsevier B.V, Netherlands, pp. S78-S79.
  • Mridha, A, Haczeyni, F, Yeh, M et al 2017, 'TLR9 is up-regulated in human and murine NASH: Pivotal role in inflammatory recruitment and cell survival', Clinical Science, vol. 131, no. 16, pp. 2145-2159pp.
  • Pok, S, Vohra, H, Wehbe, C et al. 2017, 'Deriving and testing of dysplastic murine hepatocytes: a new platform in liver cancer research', Experimental Cell Research, vol. 356, no. 1, pp. 48-56pp.
  • Haczeyni, F, Poekes, L, Wang, H et al 2017, 'Obeticholic Acid Improves Adipose Morphometry and Inflammation and Reduces Steatosis in Dietary but not Metabolic Obesity in Mice', Obesity, vol. 25, no. 1, pp. 155-165pp.
  • Truong, J, Shadbolt, B, Ooi, M et al 2017, 'Week 4 viral load predicts long-term suppression of hepatitis B virus DNA during antiviral therapy: improving hepatitis B treatment in the real world', Internal Medicine Journal, vol. 47, no. 1, pp. 50-56.
  • Haczeyni, F, Wang, H, Barn, V et al. 2017, 'The Selective Peroxisome Proliferator-Activated Receptor-Delta Agonist Seladelpar Reverses Nonalcoholic Steatohepatitis Pathology by Abrogating Lipotoxicity in Diabetic Obese Mice', Hepatology Communications, vol. 1, no. 7, pp. 663-674.
  • Mridha, A, Van Rooyen, D, Haczeyni, F et al 2017, 'NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice', Journal of Hepatology, pp. -.
  • Pok, S, Barn, V, Wong, D et al 2016, 'Testosterone regulation of cyclin E kinase: A key factor in determining gender differences in hepatocarcinogenesis', Journal of Gastroenterology and Hepatology, vol. 31, no. 6, pp. 1210-1219pp.
  • Arfianti, A, Larter, C, Lee, S et al. 2016, 'Obesity and diabetes accelerate hepatocarcinogenesis via hepatocyte proliferation independent of NF-κB or Akt/mTORC1', Journal of Clinical and Translational Research, vol. 2, no. 1, pp. 26-37pp.
  • Haczeyni, F, Wang, H, Barn, V et al 2016, 'PPAR-delta Agonist MBX-8025 Abolishes Lipotoxicity and Reverses NASH in Diabetic Obese Mice', 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, John Wiley & Sons Inc., United States, pp. 129A-129A.
  • Pok, S, Yock-Young, D, Arfianti, A et al. 2016, 'Deriving murine transformed hepatocytes in primary culture: novel technique and potential utility', Gastroenterological Society of Australia, Australian Gastroenterology Week 2016, Wiley-Blackwell Publishing Asia, Australia, pp. 4-4.
  • Ajamieh, H, Farrell, G, McCuskey, R et al 2015, 'Acute atorvastatin is hepatoprotective against ischaemia-reperfusion injury in mice by modulating eNOS and microparticle formation', Liver International, vol. 35, no. 9, pp. 2174-2186.
  • Haczeyni, F, Barn, V, Mridha, A et al 2015, 'Exercise improves adipose function and inflammation and ameliorates fatty liver disease in obese diabetic mice', Obesity, vol. 23, no. 9, pp. 1845-1855.
  • Brockhausen, J, Tay, S, Grzelak, C et al 2015, 'miR-181a mediates TGF-beta-induced hepatocyte EMT and is dysregulated in cirrhosis and hepatocellular cancer', Liver International, vol. 35, no. 1, pp. 240-253.
  • Ioannou, G, Van Rooyen, D, Savard, C et al 2015, 'Cholesterol-lowering drugs cause dissolution of cholesterol crystals and disperse Kupffer cell crown-like structures during resolution of NASH', Journal of Lipid Research, vol. 56, no. 2, pp. 277-285.
  • ZHANG, N, Chu, E, ZHANG, J et al 2014, 'Peroxisome proliferator activated receptor alpha inhibits hepatocarcinogenesis through mediating NF-kappa B signaling Pathway', Oncotarget, vol. 5, no. 18, pp. 8330-8340.
  • Teoh, N & Farrell, G 2014, 'Cholesterol Augments High Fat Diet in Accelerating Liver Carcinogenesis: Roles of NASH, Oxidative Stress, DNA Damage and Hepatocyte Proliferation', Gastroenterology, vol. 146, no. 5, pp. S927-S927.
  • Haczeyni, F, Mridha, A, Yeh, M et al 2014, 'P276 TLR9 Mediates Adipose and Liver Inflammation in Metabolically Obese Murine Models of Non-Alocholic Steatohepatitis', Journal of Hepatology, no. 60, pp. S67-S214.
  • Farrell, G, Mridha, A, Yeh, M et al. 2014, 'Strain dependence of diet-induced NASH and liver fibrosis in obese mice is linked to diabetes and inflammatory phenotype', Liver International, vol. 34, no. 7, pp. 1084-1093.
  • Teoh, N, Ajamieh, H, Wong, H et al 2014, 'Microparticles Mediate Hepatic Ischemia-Reperfusion Injury and Are The Targets of Diannexin (ASP8597)', PLOS ONE (Public Library of Science), vol. 9, no. 9, pp. e104376-e104376.
  • Gan, L, Van Rooyen, D, Teoh, N et al 2014, 'Hepatocyte free cholesterol lipotoxicity results from JNK1-mediated mitochondrial injury and is HMGB1 and TLR4-dependent', Journal of Hepatology, vol. 61, no. 6, pp. 1376-1384.
  • Chen, S, Teoh, N, Chitturi, S et al 2014, 'Coffee and Non-Alcoholic Fatty Liver Disease: Brewing evidence for hepatoprotection?', Journal of Gastroenterology and Hepatology, vol. 29, no. 3, pp. 435-441.
  • Wu, J, Shadbolt, F, Teoh, N et al. 2014, 'Influence of psychiatric diagnosis on treatment uptake and interferon side effects in patients with hepatitis C', Journal of Gastroenterology and Hepatology, vol. 29, no. 6, pp. 1258-1264.
  • Yabas, M, Coupland, L.A., Cromer, D., Winterberg, M., Teoh, N.C. D'Rozario, J., Kirk, K., Bröer, S., Paris, C.R. and A. Enders 2014, 'Mice deficient in the putative phospholipid flippase ATP11C exhibit altered erythrocyte shape, anemia, and reduced erythrocyte life span', Journal of Biological Chemistry, 289, 19531-19537.
  • Van Rooyen, D, Gan, L, Yeh, M et al 2013, 'Pharmacological cholesterol lowering reverses fibrotic NASH in obese, diabetic mice with metabolic syndrome', Journal of Hepatology, vol. 59, no. 1, pp. 144-152.
  • Larter, C, Yeh, M, Haigh, W et al. 2013, 'Dietary modification dampens liver inflammation and fibrosis in obesity-related fatty liver disease', Obesity, vol. 21, no. 6, pp. 1189-1199.
  • Pok, S, Wen, V, Shackel, N et al 2013, 'Cyclin E facilitates dysplastic hepatocytes to bypass G1/S checkpoint in hepatocarcinogenesis', Journal of Gastroenterology and Hepatology, vol. 28, no. 9, pp. 1545-1554.
  • Ajamieh, H, Farrell, G, Wong, H et al 2012, 'Atorvastatin protects obese mice against hepatic ischemia-reperfusion injury by Toll-like receptor-4 suppression and endothelial nitric oxide synthase activation', Journal of Gastroenterology and Hepatology, vol. 27, no. 8, pp. 1353-1361.
  • Shen, B, Chu, E, Zhao, G et al 2012, 'PPARgamma inhibits hepatocellular carcinoma metastases in vitro and in mice', British Journal of Cancer, vol. 106, no. 9, pp. 1486-1494.
  • Teoh, N 2012, 'Should we stop "MaS"ing about with steatotic liver grafts and "MiS" out on potential donor livers?', Journal of Gastroenterology and Hepatology, vol. 27, no. 3, pp. 422-424.
  • Ooi, M & Teoh, N 2012, 'Can long term therapy with oral nucleos(t)ide analogs influence the prognosis of chronic hepatitis B-related complications?', Journal of Gastroenterology and Hepatology, vol. 27, no. 10, pp. 1541-1543.
  • Teoh, N 2011, 'Much ado about Nutlin', Journal of Gastroenterology and Hepatology, vol. 26, no. 2, pp. 213-215.
  • Teoh, N 2011, 'Hepatic ischemia reperfusion injury: Contemporary perspectives on pathogenic mechanisms and basis for hepatoprotection-the good, bad and deadly', Journal of Gastroenterology and Hepatology, vol. 26, no. SUPPL. 1, pp. 180-187.
  • Van Rooyen, D, Larter, C, Haigh, W et al 2011, 'Hepatic free cholesterol accumulates in obese, diabetic mice and causes nonalcoholic steatohepatitis', Gastroenterology, vol. 141, no. 4, pp. 1393-U850.
  • Teoh, N 2011, 'Remote hindlimb preconditioning and hepatoprotection: NO-table strides against liver ischaemia/reperfusion injury', Clinical Science, vol. 121, no. 5-6, pp. 253-255.
  • Yabas, M., Teh, C. E., Frankenreiter, S., Lal, D., Roots, C. M., Whittle, B., Andrews, D. T., Zhang, Y., Teoh, N. C., Sprent, J., Tze, L. E., Kucharska, E. M., Kofler, J., Farell, G. C., Bröer, S., Goodnow, C. C. & Enders, A. 2011. ATP11C is critical for the internalization of phosphatidylserine and differentiation of B lymphocytes. Nature Immunology, 12, 441-449.
  • Yu, J, Shen, B, Chu, E et al 2010, 'Inhibitory role of peroxisome proliferator-activated receptor gamma in hepatocarcinogenesis in mice and in vitro', Hepatology, vol. 51, no. 6, pp. 2008-2019.
  • Teoh, N, Williams, J, Hartley, J et al 2010, 'Short-Term Therapy with Peroxisome Proliferation-Activator Receptor-Agonist Wy-14,643 Protects Murine Fatty Liver Against Ischemia-Reperfusion Injury', Hepatology, vol. 51, no. 3, pp. 996-1006.
  • Teoh, N, Farrell, G & Chan, H 2010, 'Individualisation of antiviral therapy for chronic hepatitis C', Journal of Gastroenterology and Hepatology, vol. 25, no. 7, pp. 1206-1216.
  • Teoh, N, Pyakurel, P, Dan, Y et al. 2010, 'Induction of p53 Renders ATM-Deficient Mice Refractory to Hepatocarcinogenesis', Gastroenterology, vol. 138, no. 3, pp. 1155-U451.
  • Farrell, G & Teoh, N 2010, 'Abnormal liver function tests', Australian Doctor, vol. 9 April 2010, pp. 29-36.
  • Teoh, N 2010, 'Pre-"EMT"ing key processes in liver carcinogenesis: Growing evidence for how malignant hepatocytes invade and conquer', Hepatology, vol. 52, no. 1, pp. 384-388.
  • Teoh, N, Chitturi, S & Farrell, G 2010, 'Liver Disease caused by drugs', in Mark Feldman, Lawrence S Friedman, Lawrence J. Brandt (ed.), Sleisenger and Fordtran's Gastrointestinal and Liver Disease, Elsevier, USA, pp. 1413-1431.
  • Farrell, G, Larter, C, Hou, J et al. 2009, 'Apoptosis in experimental NASH is associated with p53 activation and TRAIL receptor expression', Journal of Gastroenterology and Hepatology, vol. 24, pp. 443-452.
  • Teoh, N 2009, 'Proliferative drive and liver carcinogenesis: Too much of a good thing?', Journal of Gastroenterology and Hepatology, vol. 24, pp. 1817-1825.
  • Larter, C, Yeh, M, Van Rooyen, D et al. 2009, 'Roles of adipose restriction and metabolic factors in progression of steatosis to steatohepatitis in obese, diabetic mice', Journal of Gastroenterology and Hepatology, vol. 24, pp. 158 - 1668.
  • Ajamieh, H & Teoh, N, eds, 2009, Red wine coming up roses for intestinal ischemia reperfusion injury: Role for resveratrol?, 24.
  • Teoh, N & Bowden, F 2008, 'The case for resurrecting the long case', BMJ - British Medical Journal, vol. 336, no. 31 May 08, p. 1250.
  • Teoh, N, Dan, Y, Swisshelm, K et al 2008, 'Defective DNA Strand Break Repair Causes Chromosomal Instability and Accelerates Liver Carcinogenesis in Mice', Hepatology, vol. 47, no. 6, pp. 2078-2088.
  • Teoh, N, Fan, J & Fan, J 2008, 'Diabetes mellitus and prognosis after curative therapy for hepatocellular carcinoma: alas, still grave for the hyperglycaemic', Journal of Gastroenterology and Hepatology.
  • Farrell, G, Teoh, N & McCuskey, R 2008, 'Hepatic Microcirculation in Fatty Liver Disease', The Anatomical Record, vol. 291, pp. 684-692.
  • Teoh, N, Ito, Y, Field, J et al 2007, 'Diannexin, a Novel Annexin V Homodimer, Provides Prolonged Protection Against Hepatic Ischemia-Reperfusion Injury in Mice', Gastroenterology, vol. 133, pp. 632-646.
  • Dan, Y, Riehle, K, Lazaro, C et al 2006, 'Isolation of multipotent liver progenitor cells from human fetal liver capable of differentiating into liver and mesenchymal lineages', PNAS - Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 26, pp. 9912-9918.
  • Teoh, N & Farrell, G 2006, 'Liver Diseases Caused by Drugs', in (ed.), Sleisenger and Fordtran's Textbook of Gastrointestinal Disease (8th ed), Elsevier, United States, pp. 1807 - 1843.
  • Teoh, N & Farrell, G 2006, 'Management of chronic viral hepatitis B infection: a new era of disease control', Internal Medicine Journal, vol. 36, pp. 100 -113.
  • Teoh, N, Field, J & Farrell, G 2006, 'Interleukin-6 is a key mediator of the hepatoprotective and pro-proliferative effects of ischaemic preconditioning in mice', Journal of Hepatology, vol. 45, pp. 20 - 27.
  • Hsu, M, Qiao, L, Ho, V et al 2006, 'Ethanol reduces p38 kinase activation and cyclin D1 protein expression after partial hepatectomy in rats', Journal of Hepatology, vol. 44, pp. 375 - 382.
  • Farrell, G, ZHANG, H, Hou, J et al. 2006, 'Mechanisms of apoptosis in dietary steatohepatitis: roles of cytokines, nutrient and ER stress', Journal of Gastroenterology and Hepatology, vol. A4, p. 318.
  • Arsov, T, Larter, C, Nolan PhD, C et al. 2006, 'Adaptive failure to high-fat diet characterizes steatohepatitis in Alms1 mutant mice', Biochemical and Biophysical Research Communications, vol. 342, pp. 1152-1159.
  • Arsov, T, Larter, C, Nolan, C et al 2006, 'Adaptive failure to high-fat diet characterizes steatohepatitis in Alms1 mutant mice', Biochemical and Biophysical Research Communications, vol. 342, no. 4, pp. 1152-59.
  • Wong, G, Teoh, N, Dowsett, J et al 2005, 'Complications of Spincter of Oddi manometry: biliary-like pain versus acute pancreatitis', Scandinavian journal of gastroenterology, vol. 40, no. 2, pp. 147 - 153.
  • Teoh, N, Field, J, Sutton, J et al 2004, 'Dual role of tumor necrosis factor-a in hepatic ischemia reperfusion injury: studies in TNF-a knockout mice', Hepatology, vol. 39, pp. 412 - 421.
  • Teoh, N & Farrell, G 2003, 'Hepatotoxicity associated with non-steroidal anti-inflammatory drugs', Clinics in Liver Disease, vol. 7, no. 2, pp. 401 - 413.
  • Teoh, N & Farrell, G 2003, 'Hepatic ischemia reperfusion injury: Pathogenic mechanisms and basis for hepatoprotection', Journal of Gastroenterology and Hepatology, vol. 18, pp. 891-902.
  • Teoh, N & Farrell, G 2003, 'Hepatic ischaemia reperfusion injury. Pathogenic mechanisms and basis for protection', Journal of Gastroenterology and Hepatology, vol. 18, pp. 891 - 902.
  • Teoh, N, Leclercq, I, Pena, A et al 2003, 'Low-Dose TNF-a Protects Against Hepatic Ischemia-Reperfusion Injury in Mice: Implications for Preconditioning', Hepatology, vol. 37, no. 1, pp. 118 - 128.
  • Teoh, N, Leclercq, I, Pena, A et al 2003, 'Low-dose TNF-alpha is protective against hepatic ischemia-reperfusion injury in mice: Implications for preconditioning', Hepatology, vol. 37, no. 1, pp. 118-128.